XFOR
X4 Pharmaceuticals, Inc
Next earnings Aug 6, 2026 · consensus $-0.19 EPS, $2.32M rev
Last earnings -10.6% on 2025-11-05
$3.99▲ +49.44%
over 1Y
L $1.42EODHDH $4.66
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today—
1W-5.5%
1M-0.2%
3M-7.4%
YTD+2.6%
1Y+49.4%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Strong Buy
Revenue grew 1273.2% YoY; but unprofitable (net margin -225.6%).
X4 Pharmaceuticals, Inc shows $35.1M in FY2025 revenue (+1273.2% YoY), a -225.6% net margin, and -42.5% ROE.
Sources: SEC EDGAR (CIK 0001501697, latest 10-Q filed 2026-05-06) · as of 6/26/2026, 4:03:08 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.